Tarsier® Pharma

Pharmaceutical company developing bio-inspired medical solutions for treatment of blinding ocular diseases #Ophthalmology #Uveitis

[Tarsier® Pharma @TarsierPharma]

Thank you, Dr. @EdmundTsuiMD , for your tireless efforts to improve treatment for patients with uveitis! new endpoints will help save sight.

[Edmund Tsui, MD @EdmundTsuiMD]

📢 Our #uveitis workshop featured speakers!

Nisha Acharya, MD, MS @proctorfndn
Wiley Chambers, MD, fmr @US_FDA
Michael F. Chiang, MD @NEIDirector
Kerry Goetz, MS @NIH
Vishali Gupta, MD, @ PGIMER
Doug Jabs, MD, MBA @JohnsHopkinsSPH
Steven Piantadosi, MD, PhD @BrighamWomens

[Tarsier® Pharma @TarsierPharma]

In uveitis, particularly in cases of uveitic glaucoma, the treatment can sometimes become a significant part of the problem. Thank you, Dr. Palestine, for your honest and courageous statement.

[Tarsier® Pharma @TarsierPharma]

https://t.co/0ioyjy9qQf
June is Child Vision Awareness Month! Did you know 15% of children with JIA-associated uveitis risk blindness in one eye by adulthood? Let's protect young eyes and their future vision with better treatments!

[Tarsier® Pharma @TarsierPharma]

📢 CEO @daphnehlangford participated in NYSE Floor Talk! Grateful to Dr. Johanna (Rodriguez) Grossman, PhD, and Judy Khan Shaw for the warm welcome. Excited for future meetings at @NYSE! Stay tuned for more updates! 🚀

[NYSE 🏛 @NYSE]

.@TarsierPharma’s bio-inspired therapeutic platform is helping patients who suffer from blinding ocular diseases.

Founder + CEO Daphne Haim-Langford talks about Tarsier’s unique innovation and why this is her life mission on #NYSEFloorTalk with @JudyKShaw.

[Tarsier® Pharma @TarsierPharma]

🎉 Exciting News Alert! 🎉
Tarsier Pharma proudly welcomes Emilee Fulcher as our new Vice President of Clinical Affairs!

https://t.co/x9HhgudGEL

[Tarsier® Pharma @TarsierPharma]

Tarsier CEO @DaphneHLangford co-chaired the conference, and our COO, Zohar Milman, presented our latest progress to both in-person and virtual attendees. @OISTWEETS

[Tarsier® Pharma @TarsierPharma]

Did you know 🇮🇱 ranks second only to the 🇺🇸 as a hub for innovation in ophthalmology?
Last week, over 80 companies led by the most resilient CEOs convened at OIS@Israel to showcase remarkable advancements in medical devices, AI, and pharmaceutical ophthalmic developments. >>

[Tarsier® Pharma @TarsierPharma]

📣 Exciting news! Our CEO will co-chair OIS@Israel for the fourth time, and our COO, Zohar Milman, will present recent progress and future plans. Join us in person or virtually for this remarkable event! @OISTWEETS
register here: https://t.co/CgZxJp1WWD

[Tarsier® Pharma @TarsierPharma]

5/5 Her journey is truly remarkable, and her resilience and strong message on the need for new therapies deeply resonated with everyone present.
With the SPA agreement, TRS01 is poised to fulfill the need for new uveitic glaucoma therapy. 🌟

[Tarsier® Pharma @TarsierPharma]

1/5 Last week, we had the great honor of welcoming leading biotech analysts to the @NYSE for our 2nd Analysts Day. During the 3hr meeting in the beautiful Maps room, Tarsier management delved into the unmet medical need in uveitic glaucoma.

[Tarsier® Pharma @TarsierPharma]

4/5 The meeting began with an inspiring talk by Lissa Bachner, author of "Milo's Eyes". Despite facing daily challenges with Uveitic Glaucoma, Lissa has risen to become one of the US's leading amateur equestrians.

[Tarsier® Pharma @TarsierPharma]

Our CEO @daphnehlangford and management team will host next week our second Analysts Day, where we'll explore TRS4vision trial data, discuss FDA SPA agreement, and illuminate uveitic glaucoma market catalysts. Thanks @NYSE for hosting!

[Tarsier® Pharma @TarsierPharma]

🌟 January is #GlaucomaAwarenessMonth! 🌟 Did you know that uveitis increases the risk of rapid #glaucoma progression by almost 2x? Let's raise awareness about this connection and prioritize early detection and management. #UveiticGlaucoma #EyeHealthMatters

[Tarsier® Pharma @TarsierPharma]

@joshmarkham34 Thank you for your note. a this SPA agreement indicates that we need to conduct another trial and we de-risked the program significantly. we are doing our best to bring the TRS01 to patients ASAP.

[Tarsier® Pharma @TarsierPharma]

https://t.co/cFu0NR0jTL
Big News! Tarsier Pharma receives FDA agreement under Special Protocol Assessment for Tarsier-04 Phase 3 Trial of TRS01 Ophthalmic Solution. A major stride in treating non-infectious uveitis. FDA's support propels us closer to patients in need.

[Tarsier® Pharma @TarsierPharma]

Thrilled by Dr. Rifkin's presenting TRS4Vision trial results at the American Uveitis Society Winter Symposium in Utah! 🌟 As a uveitis expert and trial investigator, her contribution is invaluable. Thank you, Dr. Rifkin @LMR_MD

[Tarsier® Pharma @TarsierPharma]

Recent progress by our CEO @DaphneHLangford at the @OISTWEETS in San Diego
https://t.co/ZDXW5rsUoY

[Tarsier® Pharma @TarsierPharma]

Last week, our CEO, @DaphneHLangford, participated in the Cantor Healthcare Conference, where she discussed the pressing issue of blinding due to steroid complications in uveitic glaucoma patients. Stay tuned for valuable insights from this impactful event! 🌟 #UveiticGlaucoma